PACS (PACS)
Market Price (4/14/2026): $33.895 | Market Cap: $5.3 BilSector: Health Care | Industry: Health Care Facilities
PACS (PACS)
Market Price (4/14/2026): $33.895Market Cap: $5.3 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Healthcare Real Estate. Themes include Post-Acute Care Real Estate. | Weak multi-year price returns3Y Excs Rtn is -21% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 62% Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 28x Stock price has recently run up significantly6M Rtn6 month market price return is 173%, 12M Rtn12 month market price return is 270% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 140% High stock price volatilityVol 12M is 101% Short seller reportHindenburg Research report on 11/4/2024. Key risksPACS key risks include [1] potential NYSE delisting stemming from its failure to timely file financial reports and a necessary accounting restatement, Show more. |
| Megatrend and thematic driversMegatrends include Healthcare Real Estate. Themes include Post-Acute Care Real Estate. |
| Weak multi-year price returns3Y Excs Rtn is -21% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 62% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 28x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 173%, 12M Rtn12 month market price return is 270% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 140% |
| High stock price volatilityVol 12M is 101% |
| Short seller reportHindenburg Research report on 11/4/2024. |
| Key risksPACS key risks include [1] potential NYSE delisting stemming from its failure to timely file financial reports and a necessary accounting restatement, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. PACS Group, Inc. reported an earnings per share (EPS) miss for its fourth quarter of 2025, falling short of the Zacks Consensus Estimate by 9.47% with reported EPS of $0.43 against an estimate of $0.48. Despite strong revenue growth of 12.4% year-over-year to $1.36 billion, the market reacted negatively, leading to a single-day stock decline of 12.38% on February 26, 2026, the day the results were released.
2. The company faced challenges from rising operational costs and underperforming newer facilities, as highlighted during the Q4 2025 earnings call. The cost of services increased by 25% and General & Administrative expenses rose by 21% in 2025. New acquisition cohorts exhibited lower occupancy rates, with ramping facilities at 86.3% and new facilities at 81.1%, indicating that these low-occupancy, low-margin acquisitions were weighing on short-term financial results.
Show more
Stock Movement Drivers
Fundamental Drivers
The -11.7% change in PACS stock from 12/31/2025 to 4/13/2026 was primarily driven by a -17.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4132026 | Change |
|---|---|---|---|
| Stock Price ($) | 38.39 | 33.89 | -11.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 5,289 | 0.0% |
| Net Income Margin (%) | � | 3.6% | 0.0% |
| P/E Multiple | � | 27.7 | 0.0% |
| Shares Outstanding (Mil) | 129 | 157 | -17.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/13/2026| Return | Correlation | |
|---|---|---|
| PACS | -11.7% | |
| Market (SPY) | -5.4% | 25.2% |
| Sector (XLV) | -4.4% | 19.1% |
Fundamental Drivers
The 146.8% change in PACS stock from 9/30/2025 to 4/13/2026 was primarily driven by a 0.0% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 4132026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.73 | 33.89 | 146.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 5,289 | 0.0% |
| Net Income Margin (%) | � | 3.6% | 0.0% |
| P/E Multiple | � | 27.7 | 0.0% |
| Shares Outstanding (Mil) | 214 | 157 | 36.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/13/2026| Return | Correlation | |
|---|---|---|
| PACS | 146.8% | |
| Market (SPY) | -2.9% | -3.6% |
| Sector (XLV) | 6.8% | 4.1% |
Fundamental Drivers
The 201.5% change in PACS stock from 3/31/2025 to 4/13/2026 was primarily driven by a 0.0% change in the company's P/E Multiple.| (LTM values as of) | 3312025 | 4132026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.24 | 33.89 | 201.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 5,289 | 0.0% |
| Net Income Margin (%) | � | 3.6% | 0.0% |
| P/E Multiple | � | 27.7 | 0.0% |
| Shares Outstanding (Mil) | 214 | 157 | 36.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/13/2026| Return | Correlation | |
|---|---|---|
| PACS | 201.5% | |
| Market (SPY) | 16.3% | 12.1% |
| Sector (XLV) | 2.7% | 13.7% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2023 to 4/13/2026| Return | Correlation | |
|---|---|---|
| PACS | ||
| Market (SPY) | 63.3% | 13.0% |
| Sector (XLV) | 19.7% | 18.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PACS Return | - | - | - | -43% | 193% | -12% | 47% |
| Peers Return | 12% | -15% | 64% | 8% | 59% | 22% | 229% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 81% |
Monthly Win Rates [3] | |||||||
| PACS Win Rate | - | - | - | 67% | 58% | 50% | |
| Peers Win Rate | 50% | 47% | 64% | 53% | 67% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| PACS Max Drawdown | - | - | - | -44% | -41% | -21% | |
| Peers Max Drawdown | -5% | -25% | -11% | -7% | -12% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ENSG, BKD, NHC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/13/2026 (YTD)
How Low Can It Go
PACS has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to ENSG, BKD, NHC
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About PACS (PACS)
AI Analysis | Feedback
PACS is like a Marriott or Hilton for skilled nursing facilities, operating a large network of decentralized care centers with central support.
AI Analysis | Feedback
- Skilled Nursing Care: Providing specialized medical and rehabilitative services for patients requiring 24-hour in-patient services, including short-term transitional care after hospital discharge and long-term custodial care.
- Assisted Living: Offering residential care and support for seniors who need assistance with daily activities.
- Independent Living: Providing housing and a community environment for self-sufficient seniors.
AI Analysis | Feedback
PACS primarily sells its services to individuals (patients and residents) in need of post-acute and senior care. The company serves the following categories of customers:
- Individuals requiring Short-Term Transitional Skilled Nursing Care: These are patients who have been discharged from hospitals but still require 24-hour in-patient services to recuperate from acute conditions, illnesses, or serious medical procedures. This is the company's primary focus and a growing segment of their business.
- Individuals requiring Long-Term Custodial Skilled Nursing Care: While PACS's strategy is to transform facilities into higher acuity short-term care, they also serve individuals who need extended skilled nursing services for chronic conditions or ongoing care.
- Seniors and Individuals seeking Assisted Living and Independent Living: In some of its communities, PACS provides senior care, assisted living, and independent living options for individuals who need varying levels of support, from minimal assistance to more comprehensive daily living aid, but typically not requiring the same intensity of medical care as skilled nursing patients.
AI Analysis | Feedback
NULLAI Analysis | Feedback
Jason Murray, Co-Founder, CEO and Chairman
Jason Murray is the Co-Founder, CEO, and Chairman of PACS Group, Inc., which he co-founded with Mark Hancock in 2013. He has over 20 years of experience as an executive in acute and post-acute healthcare settings and is a licensed nursing home administrator. Before co-founding PACS, he worked as a healthcare executive and licensed nursing home administrator. Murray holds a master's degree in healthcare administration and was named 2023 Mountain West Entrepreneur of the Year by Ernst & Young.
Mark Hancock, Co-Founder, Executive Vice Chairman, and Interim Chief Financial Officer
Mark Hancock is a Co-Founder, Executive Vice Chairman, and Interim Chief Financial Officer of PACS Group, Inc. He co-founded the company with Jason Murray in 2013 and previously served as CFO from January 2013 until January 2024, when he was appointed Executive Vice Chairman. He was re-appointed interim CFO on September 3, 2025, following the resignation of the previous CFO. Hancock has over 20 years of experience as a finance professional. Prior to co-founding PACS, he worked as Vice President of Finance and Treasurer of Farm Credit Mid-America, a nursing home administrator at a facility affiliated with Plum Healthcare Group, Director of Corporate Finance for Steel Technologies Inc., and a Finance Manager for Ford Motor Company. He was also named a 2023 Mountain West Entrepreneur of the Year by Ernst & Young.
Josh Jergensen, President and Chief Operating Officer
Josh Jergensen is the President and Chief Operating Officer at PACS Group, Inc. He has been providing operational support to all facilities within the PACS portfolio since 2014. Jergensen is a licensed nursing home administrator and an approved preceptor in California, with more than 10 years of experience operating complex multi-story skilled nursing facilities.
John Mitchell, Chief Legal Officer and Secretary
John Mitchell serves as the Chief Legal Officer and Secretary for PACS Group, Inc., managing the company's legal department. He joined PACS in 2017. Previously, he held positions as Vice President, Legal at HCP, a NYSE-traded healthcare-focused real estate investment trust, and as Senior Vice President, Legal, and Chief Compliance Officer at Skilled Healthcare Group, a NYSE-traded skilled nursing company. He began his career at an international law firm with a focus on corporate, finance, and mergers and acquisitions.
Michelle Lewis, Executive Vice President, Chief Accounting Officer
Michelle Lewis has served as PACS Group, Inc.'s Executive Vice President, Chief Accounting Officer since January 2023. She joined the company in July 2018 and held various roles of increasing responsibility, including Controller. Before joining PACS, Ms. Lewis owned and operated her own certified public accounting firm and provided controller functions at a privately held healthcare organization.
AI Analysis | Feedback
The key risks to PACS's business are:
-
High Dependence on Government Reimbursement Programs and Regulatory Compliance: A substantial portion of PACS's revenue is generated from payments from third-party payors, particularly Medicare and Medicaid, which together accounted for 76.2% of their routine revenue in 2023 and 77.8% of total revenue in 2022. The company operates in a highly regulated industry with stringent compliance obligations, and any changes to these government reimbursement programs or failure to comply with applicable laws and regulations could result in significant expenditures, regulatory penalties, and a material adverse effect on their financial performance and operations.
-
Acquisition and Integration Strategy Risks: PACS's significant historical growth has been primarily driven by its strategy of acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care facilities. The success of this strategy relies on their expertise in identifying suitable acquisition targets, investing in clinical teams and processes, and upgrading various aspects of the business, often involving an up to three-year post-acquisition transition period. Failure to successfully execute this acquisition and integration strategy, or to effectively convert facilities to higher-value care models, could impede their growth, operational improvements, and profitability.
AI Analysis | Feedback
nullAI Analysis | Feedback
The primary addressable market for PACS is the Skilled Nursing Facility (SNF) industry in the U.S. The Centers for Medicare & Medicaid Services (CMS) expects total industry expenditures for SNFs to increase from $193.6 billion in 2022 to $283.3 billion in 2031.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for PACS
- Strategic Acquisitions and Facility Transformation: PACS's historical growth has been primarily driven by its strategy of acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care facilities. This involves investing in clinical teams and processes, upgrading technology, and improving overall operations, which is expected to continue driving revenue growth as new facilities are integrated and optimized.
- Improved Occupancy Rates and Skilled Mix: The company's operational model focuses on implementing best practices in acquired facilities, leading to significant improvements in clinical quality, occupancy rates, and skilled mix by nursing patient days (the percentage of Medicare and managed care patients). As new facilities mature and existing ones continue to optimize, these enhanced metrics are expected to contribute to increased revenue per patient day and overall revenue growth.
- Overall Expansion of the Skilled Nursing Facility (SNF) Industry: PACS operates within a growing market, with the Centers for Medicare & Medicaid Services (CMS) projecting total SNF industry expenditures to increase at a compound annual growth rate (CAGR) of 4.3% from $193.6 billion in 2022 to $283.3 billion in 2031. As one of the largest SNF operators in the United States, PACS is well-positioned to benefit from this broader industry expansion.
- Geographic Expansion: PACS anticipates further penetrating its reach into its current nine states and entering new states in the future through available acquisition opportunities. This geographic expansion will increase its total number of facilities and patient base, contributing to sustained revenue growth.
AI Analysis | Feedback
Outbound Investments
- PACS has historically grown primarily through a disciplined acquisition strategy, identifying and acquiring underperforming long-term custodial care skilled nursing facilities.
- The company focuses on converting acquired facilities into higher-value short-term transitional care facilities by investing in clinical teams, processes, technology, equipment, training, staffing, and aesthetics.
- PACS intends to explore additional purchases of real-estate assets, through purchase options or right-of-first refusals in existing leases, as well as acquisitions and de novo construction of purpose-built facilities.
Capital Expenditures
- The primary focus of capital expenditures is on implementing best practices in acquired facilities, including investments in clinical teams and processes, and upgrading technology, equipment, training, staffing, and aesthetics.
- These expenditures aim to realize and sustain the full potential of facilities during an up to three-year post-acquisition transition period.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Where Does PACS Stock Rank Among Competitors? | 02/24/2026 | |
| PACS Stock Surges 132%, With A 7-Day Winning Spree | 12/02/2025 | |
| PACS Stock Rockets 123% With 6-Day Winning Streak | 11/27/2025 | |
| PACS Stock On Fire: Up 120% With 5-Day Winning Streak | 11/26/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to PACS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 101.75 |
| Mkt Cap | 4.3 |
| Rev LTM | 4,126 |
| Op Inc LTM | 219 |
| FCF LTM | 152 |
| FCF 3Y Avg | 63 |
| CFO LTM | 311 |
| CFO 3Y Avg | 230 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 17.8% |
| Rev Chg 3Y Avg | 12.3% |
| Rev Chg Q | 8.5% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 7.1% |
| Op Mgn 3Y Avg | 6.0% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 9.4% |
| CFO/Rev 3Y Avg | 8.0% |
| FCF/Rev LTM | 3.2% |
| FCF/Rev 3Y Avg | 2.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.3 |
| P/S | 1.4 |
| P/EBIT | 16.3 |
| P/E | 24.8 |
| P/CFO | 14.5 |
| Total Yield | 3.4% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 2.5% |
| D/E | 0.4 |
| Net D/E | 0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.6% |
| 3M Rtn | 18.2% |
| 6M Rtn | 49.5% |
| 12M Rtn | 112.4% |
| 3Y Rtn | 160.5% |
| 1M Excs Rtn | -4.0% |
| 3M Excs Rtn | 20.5% |
| 6M Excs Rtn | 46.3% |
| 12M Excs Rtn | 81.6% |
| 3Y Excs Rtn | 92.7% |
Price Behavior
| Market Price | $33.89 | |
| Market Cap ($ Bil) | 5.3 | |
| First Trading Date | 04/11/2024 | |
| Distance from 52W High | -19.6% | |
| 50 Days | 200 Days | |
| DMA Price | $35.71 | $23.52 |
| DMA Trend | up | down |
| Distance from DMA | -5.1% | 44.1% |
| 3M | 1YR | |
| Volatility | 58.4% | 101.1% |
| Downside Capture | 0.59 | -0.33 |
| Upside Capture | 26.03 | 114.89 |
| Correlation (SPY) | 21.6% | 6.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.12 | 0.68 | 1.07 | -0.34 | 0.65 | 0.31 |
| Up Beta | -1.93 | 0.58 | 0.60 | 1.84 | 1.02 | 0.03 |
| Down Beta | 1.84 | 0.62 | 1.44 | -1.63 | 0.55 | -0.27 |
| Up Capture | 58% | 71% | 63% | 134% | 102% | 24% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 17 | 27 | 59 | 119 | 237 |
| Down Capture | 136% | 75% | 127% | -147% | -24% | 75% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 14 | 25 | 36 | 66 | 131 | 250 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PACS | |
|---|---|---|---|---|
| PACS | 257.3% | 100.9% | 1.67 | - |
| Sector ETF (XLV) | 8.1% | 16.3% | 0.30 | 11.7% |
| Equity (SPY) | 18.7% | 13.7% | 1.06 | 8.4% |
| Gold (GLD) | 53.7% | 27.6% | 1.55 | -7.9% |
| Commodities (DBC) | 25.2% | 16.2% | 1.37 | -6.6% |
| Real Estate (VNQ) | 14.8% | 14.0% | 0.76 | 14.2% |
| Bitcoin (BTCUSD) | -11.7% | 43.0% | -0.17 | -6.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PACS | |
|---|---|---|---|---|
| PACS | 9.0% | 85.7% | 0.61 | - |
| Sector ETF (XLV) | 6.5% | 14.6% | 0.26 | 18.5% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 12.9% |
| Gold (GLD) | 21.8% | 17.8% | 1.01 | -0.1% |
| Commodities (DBC) | 11.7% | 18.8% | 0.51 | -1.3% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 22.5% |
| Bitcoin (BTCUSD) | 4.6% | 56.6% | 0.30 | -0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PACS | |
|---|---|---|---|---|
| PACS | 4.4% | 85.7% | 0.61 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 18.5% |
| Equity (SPY) | 13.9% | 17.9% | 0.67 | 12.9% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | -0.1% |
| Commodities (DBC) | 8.8% | 17.6% | 0.42 | -1.3% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.22 | 22.5% |
| Bitcoin (BTCUSD) | 67.5% | 66.9% | 1.07 | -0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | -12.4% | -14.6% | -26.6% |
| 9/11/2025 | 24.5% | 45.5% | 69.9% |
| 11/6/2024 | -38.8% | -30.5% | -50.5% |
| 8/12/2024 | 18.8% | 23.1% | 22.2% |
| 5/13/2024 | 7.3% | 13.8% | 17.8% |
| SUMMARY STATS | |||
| # Positive | 3 | 3 | 3 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 18.8% | 23.1% | 22.2% |
| Median Negative | -25.6% | -22.6% | -38.5% |
| Max Positive | 24.5% | 45.5% | 69.9% |
| Max Negative | -38.8% | -30.5% | -50.5% |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 5.65 Bil | 5.70 Bil | 5.75 Bil | 7.5% | Higher New | Guidance: 5.30 Bil for 2025 | |
| 2026 Adjusted EBITDA | 555.00 Mil | 565.00 Mil | 575.00 Mil | 16.5% | Higher New | Guidance: 485.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dilsaver, Evelyn S | Direct | Buy | 11262025 | 29.90 | 16,724 | 499,997 | 679,828 | Form | |
| 2 | Mitchell, John Todd | Chief Legal Officer & Sec. | Direct | Sell | 11262025 | 29.89 | 159,556 | 4,768,379 | 22,588,386 | Form |
| 3 | Jergensen, Joshua | President & COO | Direct | Sell | 3172026 | 34.28 | 36,335 | 1,245,647 | 91,442,790 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.